Cancer Genetics Research News Updates
1 - 10 of 11
A Cancer-causing Gene May Benefit Patients During Chemotherapy
Published on
CHOP researchers report that a well-known gene that normally drives cancer could potentially benefit cancer patients if used in combination with chemotherapy.
Younger T Cells May Improve Immunotherapy for Children’s Cancer
Published on
CHOP is working to improve personalized cell therapy for children. Using younger T cells may offer better results against certain types of leukemia and lymphoma.
Abnormal Gene Is a Triple Threat in Driving Pediatric Brain Tumors
Published on
A CHOP oncologist co-led an international study showing that an abnormal fused gene drives children’s brain tumors by using three different biological mechanisms.
Comprehensive Cancer Gene Panels Now Available in CHOP’s Division of Genomic Diagnostics
Published on
The Division of Genomic Diagnostics at CHOP has launched a series of hereditary and somatic cancer gene panels to facilitate a precision medicine approach to cancer diagnostics.
Change in a Single DNA Base Drives a Childhood Cancer
Published on
CHOP pediatric oncology researchers have pinpointed a crucial change in a single DNA “letter” that predisposes children to an aggressive form of neuroblastoma.
CHOP Is a Founding Member of New NIH-Funded Research Consortium to Test New Cancer Treatments for Children
Published on
Building on its decades-long investigations in the biology and treatment of neuroblastoma, CHOP will lead the consortium’s neuroblastoma research program.
Pinpointing Mutations in a Relapsed Cancer May Lead to Better Treatments
Published on
CHOP neuroblastoma researchers have detailed how cancer-driving mutations evolve during chemotherapy, and they aim to exploit this knowledge to design better treatments for children.
Benefits Persist in T Cell Therapy for Children With Relapsed Leukemia
Published on
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study.
Classification of Gene Mutations in a Children’s Cancer May Point to Improved Treatments
Published on
CHOP and Penn Medicine experts are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations, setting the stage for a phase 3 clinical trial.
Cell Therapy for ALL Receives Breakthrough Therapy Designation
Published on
A personalized immunotherapy has been awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia.